# RAPA-501 Therapy of ALS Expanded Access Protocol

> **NCT06169176** · — · TEMPORARILY_NOT_AVAILABLE · sponsor: **Rapa Therapeutics LLC**

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **OTHER:** RAPA-501 Autologous T stem cells

## Key facts

- **NCT ID:** NCT06169176
- **Lead sponsor:** Rapa Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** TEMPORARILY_NOT_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-02-12

## Collaborators

- Massachusetts General Hospital
- National Institute of Neurological Disorders and Stroke (NINDS)

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06169176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06169176, "RAPA-501 Therapy of ALS Expanded Access Protocol". Retrieved via AI Analytics 2026-06-27 from https://api.ai-analytics.org/clinical/NCT06169176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*